Loading
SCN5A (Sodium channel protein type 5 subunit alpha) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.
Pore-forming subunit of Nav1.5, a voltage-gated sodium (Nav) channel that directly mediates the depolarising phase of action potentials in excitable membranes. Navs, also called VGSCs (voltage-gated sodium channels) or VDSCs (voltage-dependent sodium channels), operate by switching between closed and open conformations depending on the voltage difference across the membrane. In the open conformation they allow Na(+) ions to selectively pass through the pore, along their electrochemical gradient.
Open Targets scores its association with cancer at 0.56 (direct and indirect evidence; datatypes literature 0.95, animal model 0.38, genetic association 0.00, clinical 0.86).
In plain words · SCN5A (Sodium channel protein type 5 subunit alpha) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.
SCN5A (Sodium channel protein type 5 subunit alpha) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.
Pore-forming subunit of Nav1.5, a voltage-gated sodium (Nav) channel that directly mediates the depolarising phase of action potentials in excitable membranes.
No product in this corpus aims at SCN5A yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
Specificity not established: no corpus medicine is aimed at it and the catalogues give it only the role drug-target; HPA finds the RNA tissue enriched, which says where the protein sits but not whether the tumour differs from normal tissue. HPA SCN5A: RNA tissue enriched (heart muscle 50 nTPM); no normal tissue stained high. Distribution: no corpus cancer carries a prevalence row, threshold or catalogue link for it; Open Targets associates it with 0 specific cancer types at or above 0.5. (No rule of scripts/fetch-target-specificity.ts fired.)
Sources: Human Protein Atlas SCN5A tissue; Open Targets ENSG00000183873 associations
First described 1992. Earliest sequence paper UniProt cites for the protein: Gellens M.E. et al, Proc. Natl. Acad. Sci. U.S.A, 1992, "Primary structure and functional expression of the human cardiac tetrodotoxin-insensitive voltage-dependent sodium channel". Source.
Sources: HGNC HGNC:10593 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q14524 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000183873 (association with cancer (MONDO_0004992) 0.56; (GraphQL API, CC0))
Pore-forming subunit of Nav1.5, a voltage-gated sodium (Nav) channel that directly mediates the depolarising phase of action potentials in excitable membranes. Navs, also called VGSCs (voltage-gated sodium channels) or VDSCs (voltage-dependent sodium channels), operate by switching between closed and open conformations depending on the voltage difference across the membrane. In the open conformation they allow Na(+) ions to selectively pass through the pore, along their electrochemical gradient. The influx of Na(+) ions provokes membrane depolarisation, initiating the propagation of electrical signals throughout cells and tissues. Nav1.5 is the predominant sodium channel expressed in myocardial cells and it is responsible for the initial upstroke of the action potential in cardiac myocytes, thereby initiating the heartbeat. Required for normal electrical conduction including formation of the infranodal ventricular conduction system and normal action potential configuration, as a result of its interaction with XIRP2. Location: Cell membrane; Cytoplasm, perinuclear region; Cell membrane, sarcolemma, T-tubule; Cell junction (UniProt). Locus 3p22.2 (HGNC).
RNA: tissue enriched (heart muscle 50 nTPM), detected in some normal tissues.
No normal tissue stained high.
No cancer sample stained medium or high.
HPA SCN5A tissue · HPA SCN5A pathology · HPA protein class: FDA approved drug targets
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"SCN5A" OR ABSTRACT:"SCN5A" OR TITLE:"sodium voltage-gated channel alpha subunit 5" OR ABSTRACT:"sodium voltage-gated channel alpha subunit 5" OR TITLE:"Sodium channel protein type 5 subunit alpha" OR ABSTRACT:"Sodium channel protein type 5 subunit alpha" OR TITLE:"Nav1.5" OR ABSTRACT:"Nav1.5" OR TITLE:"LQT3" OR ABSTRACT:"LQT3" OR TITLE:"HB1" OR ABSTRACT:"HB1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about SCN5A, not a curated reading list.